Anti-Inflammatory Effect of Surfactant Lipid in the Vaginal Mucosa

A Pilot Study

Colin Macneill, Glendell S. De Guzman, Kate Lupo, Todd Umstead, David Phelps, Joanna Floros

Research output: Contribution to journalArticle

Abstract

Objective The aim of the study was to test the hypothesis that vaginal administration of surfactant lipids, which may counter-balance the proinflammatory effects of vaginal surfactant protein A, will decrease proinflammatory cytokines and increase anti-inflammatory cytokines in vaginal mucosal fluid in healthy women. Materials and Methods Three groups of healthy cycling women were randomized to receive vaginally a single dose of the following: (1) low-dose calfactant, a type of surfactant lipids, 0.8 mg/ml; (2) high-dose calfactant 8.0 mg/ml; or (3) placebo, at the time of resolution of menses. Vaginal mucosal fluid was collected before administration and also 1 and 8 days after administration of each treatment. After 1 mo, each group was randomized to each alternative treatment; thus, for a 3-month treatment period, each group received each of the 3 treatments. Vaginal fluid was tested using a Multiplex Immunoassay System. Cytokine concentrations on day 1 and day 8 were compared with day zero and tested for significance with the Student's t test. Results Six healthy subjects completed each treatment. Subjects given high-dose calfactant had, by day 8, a significant reduction in macrophage chemotactic protein-1 and interleukin 15 (IL-15) compared with low-dose calfactant or placebo. High-dose calfactant resulted in an increase in anti-inflammatory cytokines that trended toward significance on day 1 (IL-1RA) or day 8 (IL-10). Conclusions This pilot study in healthy women demonstrates that calfactant reduces proinflammatory cytokines and increases anti-inflammatory cytokines in the vagina. We propose that calfactant may be an effective vaginal anti-inflammatory therapy for inflammatory vaginitis and similar disorders for which current therapy is ineffective.

Original languageEnglish (US)
Pages (from-to)71-74
Number of pages4
JournalJournal of Lower Genital Tract Disease
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Surface-Active Agents
Mucous Membrane
Anti-Inflammatory Agents
Lipids
Cytokines
Therapeutics
Placebos
Intravaginal Administration
Pulmonary Surfactant-Associated Protein A
Vaginitis
Interleukin-15
Menstruation
Vagina
calfactant
Interleukin-1
Immunoassay
Interleukin-10
Healthy Volunteers
Macrophages
Students

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

@article{3612ce51c8bf4863954906e17adfded3,
title = "Anti-Inflammatory Effect of Surfactant Lipid in the Vaginal Mucosa: A Pilot Study",
abstract = "Objective The aim of the study was to test the hypothesis that vaginal administration of surfactant lipids, which may counter-balance the proinflammatory effects of vaginal surfactant protein A, will decrease proinflammatory cytokines and increase anti-inflammatory cytokines in vaginal mucosal fluid in healthy women. Materials and Methods Three groups of healthy cycling women were randomized to receive vaginally a single dose of the following: (1) low-dose calfactant, a type of surfactant lipids, 0.8 mg/ml; (2) high-dose calfactant 8.0 mg/ml; or (3) placebo, at the time of resolution of menses. Vaginal mucosal fluid was collected before administration and also 1 and 8 days after administration of each treatment. After 1 mo, each group was randomized to each alternative treatment; thus, for a 3-month treatment period, each group received each of the 3 treatments. Vaginal fluid was tested using a Multiplex Immunoassay System. Cytokine concentrations on day 1 and day 8 were compared with day zero and tested for significance with the Student's t test. Results Six healthy subjects completed each treatment. Subjects given high-dose calfactant had, by day 8, a significant reduction in macrophage chemotactic protein-1 and interleukin 15 (IL-15) compared with low-dose calfactant or placebo. High-dose calfactant resulted in an increase in anti-inflammatory cytokines that trended toward significance on day 1 (IL-1RA) or day 8 (IL-10). Conclusions This pilot study in healthy women demonstrates that calfactant reduces proinflammatory cytokines and increases anti-inflammatory cytokines in the vagina. We propose that calfactant may be an effective vaginal anti-inflammatory therapy for inflammatory vaginitis and similar disorders for which current therapy is ineffective.",
author = "Colin Macneill and {De Guzman}, {Glendell S.} and Kate Lupo and Todd Umstead and David Phelps and Joanna Floros",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/LGT.0000000000000448",
language = "English (US)",
volume = "23",
pages = "71--74",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Anti-Inflammatory Effect of Surfactant Lipid in the Vaginal Mucosa : A Pilot Study. / Macneill, Colin; De Guzman, Glendell S.; Lupo, Kate; Umstead, Todd; Phelps, David; Floros, Joanna.

In: Journal of Lower Genital Tract Disease, Vol. 23, No. 1, 01.01.2019, p. 71-74.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-Inflammatory Effect of Surfactant Lipid in the Vaginal Mucosa

T2 - A Pilot Study

AU - Macneill, Colin

AU - De Guzman, Glendell S.

AU - Lupo, Kate

AU - Umstead, Todd

AU - Phelps, David

AU - Floros, Joanna

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective The aim of the study was to test the hypothesis that vaginal administration of surfactant lipids, which may counter-balance the proinflammatory effects of vaginal surfactant protein A, will decrease proinflammatory cytokines and increase anti-inflammatory cytokines in vaginal mucosal fluid in healthy women. Materials and Methods Three groups of healthy cycling women were randomized to receive vaginally a single dose of the following: (1) low-dose calfactant, a type of surfactant lipids, 0.8 mg/ml; (2) high-dose calfactant 8.0 mg/ml; or (3) placebo, at the time of resolution of menses. Vaginal mucosal fluid was collected before administration and also 1 and 8 days after administration of each treatment. After 1 mo, each group was randomized to each alternative treatment; thus, for a 3-month treatment period, each group received each of the 3 treatments. Vaginal fluid was tested using a Multiplex Immunoassay System. Cytokine concentrations on day 1 and day 8 were compared with day zero and tested for significance with the Student's t test. Results Six healthy subjects completed each treatment. Subjects given high-dose calfactant had, by day 8, a significant reduction in macrophage chemotactic protein-1 and interleukin 15 (IL-15) compared with low-dose calfactant or placebo. High-dose calfactant resulted in an increase in anti-inflammatory cytokines that trended toward significance on day 1 (IL-1RA) or day 8 (IL-10). Conclusions This pilot study in healthy women demonstrates that calfactant reduces proinflammatory cytokines and increases anti-inflammatory cytokines in the vagina. We propose that calfactant may be an effective vaginal anti-inflammatory therapy for inflammatory vaginitis and similar disorders for which current therapy is ineffective.

AB - Objective The aim of the study was to test the hypothesis that vaginal administration of surfactant lipids, which may counter-balance the proinflammatory effects of vaginal surfactant protein A, will decrease proinflammatory cytokines and increase anti-inflammatory cytokines in vaginal mucosal fluid in healthy women. Materials and Methods Three groups of healthy cycling women were randomized to receive vaginally a single dose of the following: (1) low-dose calfactant, a type of surfactant lipids, 0.8 mg/ml; (2) high-dose calfactant 8.0 mg/ml; or (3) placebo, at the time of resolution of menses. Vaginal mucosal fluid was collected before administration and also 1 and 8 days after administration of each treatment. After 1 mo, each group was randomized to each alternative treatment; thus, for a 3-month treatment period, each group received each of the 3 treatments. Vaginal fluid was tested using a Multiplex Immunoassay System. Cytokine concentrations on day 1 and day 8 were compared with day zero and tested for significance with the Student's t test. Results Six healthy subjects completed each treatment. Subjects given high-dose calfactant had, by day 8, a significant reduction in macrophage chemotactic protein-1 and interleukin 15 (IL-15) compared with low-dose calfactant or placebo. High-dose calfactant resulted in an increase in anti-inflammatory cytokines that trended toward significance on day 1 (IL-1RA) or day 8 (IL-10). Conclusions This pilot study in healthy women demonstrates that calfactant reduces proinflammatory cytokines and increases anti-inflammatory cytokines in the vagina. We propose that calfactant may be an effective vaginal anti-inflammatory therapy for inflammatory vaginitis and similar disorders for which current therapy is ineffective.

UR - http://www.scopus.com/inward/record.url?scp=85059027467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059027467&partnerID=8YFLogxK

U2 - 10.1097/LGT.0000000000000448

DO - 10.1097/LGT.0000000000000448

M3 - Article

VL - 23

SP - 71

EP - 74

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 1

ER -